Bisphosphonate use and risk of colorectal cancer: A systematic review and meta-analysis

British Journal of Clinical Pharmacology

Volumn 76, Issue 3, 2013, Pages 329-337

  Bonovas, Stefanos ^a,b,c   Nikolopoulos, Georgios ^b,d   Bagos, Pantelis ^c  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^b Hellenic Centre for Disease Control and Prevention   (Greece)

^c UNIVERSITY OF CENTRAL GREECE   (Greece)

^d NATIONAL DEVELOPMENT AND RESEARCH INSTITUTES   (United States)

Author keywords

Bisphosphonates; Colorectal cancer; Meta analysis

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; CLODRONIC ACID; ETIDRONIC ACID; IBANDRONIC ACID; PAMIDRONIC ACID; RISEDRONIC ACID; ZOLEDRONIC ACID;

ARTICLE; CANCER RISK; COLORECTAL CANCER; HUMAN; MEDLINE; META ANALYSIS; OBSERVATIONAL STUDY; PRIORITY JOURNAL; PUBLISHING; RISK FACTOR; SYSTEMATIC REVIEW;

BISPHOSPHONATES; COLORECTAL CANCER; META-ANALYSIS;

ANTICARCINOGENIC AGENTS; COLORECTAL NEOPLASMS; DATABASES, FACTUAL; DIPHOSPHONATES; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; RISK; TIME FACTORS;

EID: 84882696298     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/bcp.12135     Document Type: Article

References (42)

1. Rosen CJ. Clinical practice. Postmenopausal osteoporosis. N Engl J Med 2005; 353: 595-603.
2. Qaseem A, Snow V, Shekelle P, Hopkins R Jr, Forciea MA, Owens DK, Clinical Efficacy Assessment Subcommittee of the American College of Physicians. Pharmacologic treatment of low bone density or osteoporosis to prevent fractures: a clinical practice guideline from the American College of Physicians. Ann Intern Med 2008; 149: 404-415.
3. Kanis JA, Burlet N, Cooper C, Delmas PD, Reginster JY, Borgstrom F, Rizzoli R, European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO). European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos Int 2008; 19: 399-428.
4. Van Poznak CH, Temin S, Yee GC, Janjan NA, Barlow WE, Biermann JS, Bosserman LD, Geoghegan C, Hillner BE, Theriault RL, Zuckerman DS, Von Roenn JH, American Society of Clinical Oncology. American Society of Clinical Oncology executive summary of the clinical practice guideline update on the role of bone-modifying agents in metastatic breast cancer. J Clin Oncol 2011; 29: 1221-1227.
5. Udell JA, Fischer MA, Brookhart MA, Solomon DH, Choudhry NK. Effect of the Women's Health Initiative on osteoporosis therapy and expenditure in Medicaid. J Bone Miner Res 2006; 21: 765-771.
6. Watson J, Wise L, Green J. Prescribing of hormone therapy for menopause, tibolone, and bisphosphonates in women in the UK between 1991 and 2005. Eur J Clin Pharmacol 2007; 63: 843-849.
7. Suri S, Mönkkönen J, Taskinen M, Pesonen J, Blank MA, Phipps RJ, Rogers MJ. Nitrogen-containing bisphosphonates induce apoptosis of Caco-2 cells in vitro by inhibiting the mevalonate pathway: a model of bisphosphonate-induced gastrointestinal toxicity. Bone 2001; 29: 336-343.
8. Sassa S, Okabe H, Nemoto N, Kikuchi H, Kudo H, Sakamoto S. Ibadronate may prevent colorectal carcinogenesis in mice with ulcerative colitis. Anticancer Res 2009; 29: 4615-4619.
9. Todaro M, D'Asaro M, Caccamo N, Iovino F, Francipane MG, Meraviglia S, Orlando V, La Mendola C, Gulotta G, Salerno A, Dieli F, Stassi G. Efficient killing of human colon cancer stem cells by gammadelta T lymphocytes. J Immunol 2009; 182: 7287-7296.
10. Sewing L, Steinberg F, Schmidt H, Goke R. The bisphosphonate zoledronic acid inhibits the growth of HCT-116 colon carcinoma cells and induces tumor cell apoptosis. Apoptosis 2008; 13: 782-789.
11. Rennert G, Pinchev M, Rennert HS, Gruber SB. Use of bisphosphonates and reduced risk of colorectal cancer. J Clin Oncol 2011; 29: 1146-1150.
12. Khalili H, Huang ES, Ogino S, Fuchs CS, Chan AT. A prospective study of bisphosphonate use and risk of colorectal cancer. J Clin Oncol 2012; 30: 3229-3233.
13. Green J, Czanner G, Reeves G, Watson J, Wise L, Beral V. Oral bisphosphonates and risk of cancer of oesophagus, stomach, and colorectum: case-control analysis within a UK primary care cohort. BMJ 2010; 341: c4444.
14. Jüni P, Witschi A, Bloch R, Egger M. The hazards of scoring the quality of clinical trials for meta-analysis. JAMA 1999; 282: 1054-1060.
15. Greenland S. Invited commentary: a critical look at some popular meta-analytic methods. Am J Epidemiol 1994; 140: 290-296.
16. Greenland S. Quantitative methods in the review of epidemiologic literature. Epidemiol Rev 1987; 9: 1-30.
17. Petitti DB, ed. Statistical methods in meta-analysis. In: Meta-Analysis, Decision Analysis and Cost-Effectiveness Analysis. New York: Oxford University Press, 1994; 90-114.
18. Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics 1994; 50: 1088-1101.
19. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997; 315: 629-634.
20. Cochran WG. The combination of estimates from different experiments. Biometrics 1954; 8: 101-129.
21. Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med 2002; 21: 1539-1558.
22. Higgins JP, Green S, eds. Cochrane Handbook for Systematic Reviews of Interventions. Chichester: Wiley, 2008.
23. Tobias A. Assessing the influence of a single study in the meta-analysis estimate. Stata Techn Bull 1999; 8: 15-17.
24. Hill AB. The environment and disease: association or causation? Proc R Soc Med 1965; 58: 295-300.
25. Stroup DF, Berlin JA, Morton SC, Olkin I, Williamson GD, Rennie D, Moher D, Becker BJ, Sipe TA, Thacker SB. Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. JAMA 2000; 283: 2008-2012.
26. Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med 2009; 151: 264-269 W64.
27. Chiang CH, Huang CC, Chan WL, Huang PH, Chen TJ, Chung CM, Lin SJ, Chen JW, Leu HB. Oral alendronate use and risk of cancer in postmenopausal women with osteoporosis: a nationwide study. J Bone Miner Res 2012; 27: 1951-1958.
28. Pazianas M, Abrahamsen B, Eiken PA, Eastell R, Russell RG. Reduced colon cancer incidence and mortality in postmenopausal women treated with an oral bisphosphonate - Danish National Register Based Cohort Study. Osteoporos Int 2012; 23: 2693-2701.
29. Cardwell CR, Abnet CC, Veal P, Hughes CM, Cantwell MM, Murray LJ. Exposure to oral bisphosphonates and risk of cancer. Int J Cancer 2012; 131: E717-725.
30. Singh H, Nugent Z, Demers A, Mahmud S, Bernstein C. Exposure to bisphosphonates and risk of colorectal cancer: a population-based nested case-control study. Cancer 2012; 118: 1236-1243.
31. Vestergaard P. Occurrence of gastrointestinal cancer in users of bisphosphonates and other antiresorptive drugs against osteoporosis. Calcif Tissue Int 2011; 89: 434-441.
32. Nikolopoulos GK, Bagos PG, Bonovas S. Developing the evidence base for cancer chemoprevention: use of meta-analysis. Curr Drug Targets 2011; 12: 1989-1997.
33. Simes JR. Publication bias: the case for an international registry of trials. J Clin Oncol 1986; 4: 1529-1541.
34. Sterling TD, Rosenbaum WL, Weinkam JJ. Publication decisions revisited: the effect of the outcome of statistical tests on the decision to publish and vice versa. Am Statist 1995; 49: 108-112.
35. Schmidt C. New studies support case for bisphosphonates as possible chemopreventive agent. J Natl Cancer Inst 2010; 102: 453-455.
36. Nelson RL, Turyk M, Kim J, Persky V. Bone mineral density and the subsequent risk of cancer in the NHANES I follow-up cohort. BMC Cancer 2002; 2: 22.
37. Zhang Y, Felson DT, Ellison RC, Kreger BE, Schatzkin A, Dorgan JF, Cupples LA, Levy D, Kiel DP. Bone mass and the risk of colon cancer among postmenopausal women: the Framingham study. Am J Epidemiol 2001; 153: 31-37.
38. Ganry O, Lapotre-Ledoux B, Fardellone P, Dubreuil A. Bone mass density, subsequent risk of colon cancer and survival in postmenopausal women. Eur J Epidemiol 2008; 23: 467-473.
39. Stresing V, Daubiné F, Benzaid I, Mönkkönen H, Clézardin P. Bisphosphonates in cancer therapy. Cancer Lett 2007; 257: 16-35.
40. Clézardin P. The antitumor potential of bisphosphonates. Semin Oncol 2002; 29: 33-42.
41. Wood J, Bonjean K, Ruetz S, Bellahcène A, Devy L, Foidart JM, Castronovo V, Green JR. Novel antiangiogenic effects of the bisphosphonate compound zoledronic acid. J Pharmacol Exp Ther 2002; 302: 1055-1061.
42. Pazianas M, Russell RG. Potential therapeutic effects of oral bisphosphonates on the intestine. Ann N Y Acad Sci 2011; 1240: E19-25.